Laura Joszt, MA

The phase 3 IMerge trial (NCT02598661) evaluated how treatment with imetelstat impacts health-related quality of life in patients with lower-risk myelodysplastic syndromes (MDS), according to María Díez Campelo, MD, PhD.

Risk factors can vary for dry eye, a condition that affects the layers of tear film on the eye, says Nicole Bajic, MD.

The CMS Bundled Payment for Care Improvement (BPCI) Advanced model was successful at reducing spending for outpatient procedures for patients receiving back and neck except spinal fusion treatments or procedures.

During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.

Racial disparities in childhood obesity have risen due to social determinants, food insecurity, and systemic barriers, impacting minority communities across the US.

Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic kidney disease.

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more targeted public health efforts.

Artificial intelligence (AI) transforms oncology by enhancing clinical decision-making, improving patient outcomes, and shaping future health care training, as discussed by experts at Tennessee Oncology's “Tech Innovations in Community Oncology."

During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.

US ovarian cancer mortality rates declined from 1999 to 2020, but significant disparities remain across age, race, and geographic regions, highlighting the need for targeted public health efforts.

Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile.

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."

The decision could have ripple effects across the country when it comes to state governments deciding who gets to receive Medicaid funds, says Jennifer Evans, JD.

Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.

The indirect comparative analysis is the first of its kind to assess the relative efficacy of approved covalent Bruton tyrosine kinase inhibitors (cBTKis) in the absence of head-to-head trials.

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

The Braidwood decision maintains the status quo for many patients, keeping preventive services covered by Medicaid under the Affordable Care Act (ACA), says Jeff Fitzgerald, JD.

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in myeloproliferative neoplasms.

There are significant racial disparities in outpatient referrals for opioid use disorder treatment, highlighting urgent need for targeted interventions in emergency care, according to a recent study.

In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy benefit manager reform, and implications for manufacturers and patients.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).

Nicolas Ferreyros, managing director, Community Oncology Alliance, discusses key components of health equity and social determinants of health that need to be addressed in cancer care.

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, says Mansi Shah, MD.

Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, primarily due to lower administration costs and improved patient quality of life, said Ivo Abraham, PhD, RN, of The University of Arizona.

Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of life and emotional well-being.

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple myeloma.

CK Wang, MD, chief medical officer of COTA, discusses how real-world data help identify disparities and gaps in cancer care.

Revumenib for relapsed/refractory acute leukemias with KMT2A translocation is cost-neutral for health plans, but traditional methods of analysis may not be accurate for rare diseases, said Ivo Abraham, PhD, RN, of The University of Arizona.